Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Government-funded Hong Kong Startup Looks To Run Traditional Chinese Medicine Treatment For IBS Through Clinical Trials

This article was originally published in PharmAsia News

Executive Summary

HONG KONG - Developing a treatment for irritable bowel syndrome has proven to be an elusive goal and there is no product available in Asia to fully treat the disease, but a government-funded Hong Kong startup hopes a traditional Chinese medicine can stand the rigors of pharmaceutical approvals and fill an unmet medical need

You may also be interested in...



Sucampo/Takeda’s Amitiza First To Fill Zelnorm Void In IBS Market

With the addition of an irritable bowel syndrome indication, Sucampo Pharmaceuticals has expanded the market opportunity for its chronic idiopathic constipation drug Amitiza by about 20 million patients

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).

UsernamePublicRestriction

Register

LL1132553

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel